Pasar al contenido principal

NUEVAS TERAPIAS ANTIVIRALES E INMUNOMODULADORAS DE AMPLIO ESPECTRO FRENTE A FACTORES CELULARES DEL HUESPED

PID2023-147498OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PRIVADA INSTITUT DE RECERCA SOBRE IMMUNOPATOLOGIES-CAIXA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m 6 A protein synthesis routes

  • Molina Molina, Elisa
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • Franco-Trepat, Eloi
  • Jarne, Ignasi
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Badia, Roger|||0000-0003-3982-7577
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Revilla, Lluís
  • Franco Cirera, Sandra|||0000-0003-4126-2202
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Roca, Núria
  • Ceada, Gerardo|||0000-0002-0524-4018
  • Kochanowski, Karl|||0000-0002-1884-7694
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Boreika, Rytis|||0000-0001-6720-1577
  • Bordoy, Antoni E.|||0000-0002-1165-542X
  • Soler, Laia|||0009-0000-4122-5079
  • Guil, Sonia|||0000-0002-2257-3331
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
  • Martinez, Miguel Angel|||0000-0002-6681-4950
  • Paredes, Roger|||0000-0002-6553-691X
  • Losada, Alejandro
  • Avilés, Pablo
  • Cuevas, Carmen
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Ballana, Ester|||0000-0002-5215-7363
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
Plitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preserving cellular viability. In response to plitidepsin, cells upregulate EIF2AK3 and proteins that reduce translation, but also proteins that support proteostasis via ribosome synthesis and cap-independent translation by eIF4G2 and IGF2BP2. While plitidepsin inhibits cap- or internal ribosome entry sites (IRES)-mediated translation, its impact on N6-methyladenosine (m 6 A) translation is limited. In agreement, plitidepsin blocks members of Coronaviridae, Flaviviridae, Pneumoviridae and Herpesviridae families. Yet, it fails to inhibit retroviruses that exploit m 6 A synthesis routes and are blocked by drugs targeting IGF2BP2 m 6 A reader. By deciphering the molecular fingerprint of cells treated with therapies targeting translation we identify a rational approach to select broad-spectrum antivirals with potential to counteract future pandemic viruses. By deciphering the molecular fingerprint of cells treated with host-directed therapies targeting protein translation, the authors identified a rational approach to select for broad-spectrum antivirals with potential to counteract future pandemic viruses.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model

  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Pérez, Mònica
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Tondelli, Barbara
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Capdevila, Sara
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Urrea, Víctor|||0000-0002-2577-856X
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Ballana, Ester|||0000-0002-5215-7363
  • Forrow, Stephen
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Blanco, Julià|||0000-0002-2225-0217
K18-hACE2 mice express high levels of the human protein angiotensin-converting enzyme 2 (ACE2), the receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and are therefore susceptible to infection by this virus. These animals have been crucial to understanding viral pathogenesis and to testing coronavirus disease 2019 (COVID-19) vaccines and antiviral drugs. However, K18-hACE2 often dies after infection with initial SARS-CoV-2 variants, likely due to a massive brain infection that does not occur in humans. Here, we used a technology known as knock-in (KI) that allows for the targeted insertion of a gene into a mouse, and we have generated a new human ACE2 (hACE2) mouse. We have characterized this new animal model demonstrating that, upon challenge with SARS-CoV-2, the virus replicates in the respiratory tract, damaging lung tissue and causing inflammation. In contrast to K18-hACE2 mice, only limited or no brain infection could be detected in this new model. After 14 days, most animals recovered from the infection, although lung tissue lesions were still observed. This new model could be instrumental for the study of specific disease aspects such as post-COVID-19 condition, sequelae, and susceptibility to reinfection.
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes

  • Molina Molina, Elisa
  • Bech-Serra, Joan Josep
  • Franco-Trepat, Eloi
  • Jarne, Ignasi
  • Perez-Zsolt, Daniel
  • Badia, Roger
  • Riveira-Muñoz, Eva
  • Garcia-Vidal, Edurne
  • Revilla, Lluís
  • Franco, Sandra
  • Tarrés Freixas, Ferran
  • Roca, Núria
  • Ceada, Gerardo
  • Kochanowski, Karl
  • Raïch-Regué, Dàlia
  • Erkizia, Itziar
  • Boreika, Rytis
  • Bordoy, Antoni E.
  • Soler, Laia
  • Guil, Sonia
  • Carrillo, Jorge
  • Blanco, Julià
  • Martínez, Miguel Ángel
  • Paredes, Roger
  • Losada, Alejandro
  • Aviles, Pablo
  • Cuevas, Carmen
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Ballana, Ester
  • de la Torre, Carolina
  • Izquierdo-Useros, Nuria
Plitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preserving cellular viability. In response to plitidepsin, cells upregulate EIF2AK3 and proteins that reduce translation, but also proteins that support proteostasis via ribosome synthesis and cap-independent translation by eIF4G2 and IGF2BP2. While plitidepsin inhibits cap- or internal ribosome entry sites (IRES)-mediated translation, its impact on N6-methyladenosine (m6A) translation is limited. In agreement, plitidepsin blocks members of Coronaviridae, Flaviviridae, Pneumoviridae and Herpesviridae families. Yet, it fails to inhibit retroviruses that exploit m6A synthesis routes and are blocked by drugs targeting IGF2BP2 m6A reader. By deciphering the molecular fingerprint of cells treated with therapies targeting translation we identify a rational approach to select broad-spectrum antivirals with potential to counteract future pandemic viruses., N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2020-117145RB-I00, PID2023-147498OB-I00 and 10.13039/501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union) and by institutional funding of PharmaMar, Grifols, HIPRA, and Amassence. E.M-M. is supported by the Spanish Ministry of Science and Innovation (grant PRE2021-099271). E.F-T is supported by JDC2023-050389-I funded by MCIU/AEI/10.13039/501100011033 and FSE+. E.G-V. is a research fellow from PERIS (SLT017/20/000090). E.B. and R.B. are research fellows from ISCIII-FIS (CPII19/00012; CP19/00011). K.K. is supported by funding from the Spanish Ministry of Research and Innovation (RYC2021-033035-I/AEI/10.13039/501100011033). G.C. is supported with funding from PLEC2022-009171/AEI/10.13039/501100011033. IrsiCaixa is supported by 2021 SGR 0045. The proteomic analyses were conducted at the IJC Proteomics Unit, which is affiliated with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Spanish Platform of Molecular and Bioinformatics Resources (ProteoRed), Instituto de Salud Carlos III (PT17/0019), and CERCA GINYNS. This unit serves as a gateway to scientific and technical infrastructures. We acknowledge J. Díaz from the CMCiB for his constant help at the BSL3 facility. We thank the contribution of E. Martró and V. Saludes from the Microbiology department of HUGTIP for their constant help to identify and sequence SARS-CoV-2 variants. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com) and Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real-time PCR system and an Eclipse Ts2RFL inverted research microscope., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Optimized ACE2-Fc fusion proteins with picomolar neutralization activity against highly evolved SARS-CoV-2 variants

  • Abancó, Ferran
  • Tarrés Freixas, Ferran
  • Lepore, Rosalba
  • Molina-Molina, Elisa
  • Franco, Eloi
  • Boreika, Rytis
  • Pradenas, Edwards
  • Raïch-Regué, Dàlia
  • Erkizia, Itziar
  • Clotet, Bonaventura
  • Valencia, Alfonso
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Trinité, Benjamin
The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compromised the efficacy of many authorized monoclonal antibody products. This highlights the need for alternative strategies, especially for vulnerable populations such as immunocompromised individuals. Here, we optimized angiotensin-converting enzyme 2 (ACE2)-Fc fusion proteins by combining three engineering steps: in silico mutagenesis of the S protein binding interface to increase affinity, insertion of a flexible linker to improve protein stability and S protein accessibility, and generation of a tetrameric molecule to maximize avidity. Neutralizing activity was tested against a large panel of pre-Omicron and Omicron pseudoviruses and authentic viruses, including JN.1 and KP.2 variants. Optimized ACE2-Fc molecules demonstrated potent neutralizing activity, in the picomolar range, against all SARS-CoV-2 variants. Our molecules displayed similar potency but better resilience when compared to the monoclonal antibody Sipavibart. These findings support ACE2-Fc proteins as robust candidates for next-generation interventions against infection by an evolving SARS-CoV-2., We acknowledge Carmen Aguilar-Gurrieri from IrsiCaixa for her help on initial structural analysis and Jorge Díaz from CMCiB for his help at the BSL3 facility. We also acknowledge Carlo Carolis and Katrina Broadbent from CRG for their work on surface plasmon resonance. Benjamin Trinité was funded by Project DTS23009 from the Spanish “Instituto de Salud Carlos III (ISCIII)-Subdirección General de Evaluación” and “Fondo Europeo de Desarrollo Regional (FEDER).” Julià Blanco was partially funded by the crowdfunding initiative #joemcorono, GRIFOLS, and the Fundació Glòria Soler. Nuria Izquierdo-Useros is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 and 10.13039/501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and by institutional funding from PharmaMar, GRIFOLS, HIPRA, and Amassence. Eloi Franco is supported by JDC2023-050389-I funded by MCIU/AEI/10.13039/501100011033 and FSE+. IrsiCaixa and IRTA are funded by the CERCA program/Generalitat de Catalunya. We acknowledge the funding from 2021-SGR-00651 project, 2021-SGR-01385, and 2021-SGR-00825 projects by the Generalitat de Catalunya., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Airway organoids reveal patterns of influenza A tropism and adaptation in wildlife species

  • Tarrés Freixas, Ferran
  • Ceada, Gerardo
  • Català-Moll, Francesc
  • Casadellà, Maria
  • Tolosa-Alarcón, Sara
  • Franco-Trepat, Eloi
  • Boreika, Rytis
  • Almagro-Delgado, Vanessa
  • Carmona, Noelia
  • Estruch, Josep
  • Fernández-Bellon, Hugo
  • Fuentes-Moyano, Laura
  • Molina-López, Rafael
  • Navarro, Nuria
  • Parera, Mariona
  • Pérez Simó, Marta
  • Repullés, Joan
  • Roca, Núria
  • Torne, Odalys
  • Velarde, Roser
  • Valencia, Alfonso
  • Paredes, Roger
  • Izquierdo-Useros, Nuria
  • Romero-Durana, Miguel
  • Kochanowski, Karl
  • Vergara-Alert, Júlia
Identifying animal species that are susceptible to the plethora of existing and emerging viruses is critical for predicting and containing disease outbreaks. Current efforts to assess viral tropism largely rely on experimental infection models, but such experiments are logistically and ethically infeasible for many wildlife species. To tackle this challenge, we developed a panel of airway organoids from ten taxonomically diverse wildlife and livestock species and evaluated their susceptibility to influenza viruses of mammalian (pH1N1) and avian (H5N1) origin. Our analyses revealed large host-specific differences in infection rate and cytopathogenicity that aligned with known in vivo data and field observations. Furthermore, we demonstrated that this organoid panel can serve as a powerful tool to elucidate receptor-binding mechanisms, viral dynamics and early host adaptation in poorly characterized animal hosts. In summary, this work provides a robust and ethically viable approach for evaluating viral tropism and adaptation in wildlife species, and may aid current pandemic preparedness, zoonotic disease surveillance and wildlife conservation efforts., This project was supported by a “Proyectos en lineas estratégicas” grant from the Spanish Ministry of Research and Innovation (project ID: PLEC2022-009171 /AEI/10.13039/501100011033). KK acknowledges additional support by the Spanish Ministry of Research and Innovation (RYC2021-033035-I /AEI/10.13039/501100011033). N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 /AEI/10.13039/501100011033), EU HORIZON-HLTH-2021 CORONA-01 (grant 101046118), EU HORIZON-HLTH-2023-DISEASE-03, and by institutional funding from PharmaMar, HIPRA, Amassence and Smart Vitamins. NIU is part of PTI-CSIC Salud Global. The authors also thank the support of CERCA and Fundación Dormeur. E.F.-T. is supported by JDC2023050389-I. MRD was supported by a fellowship within the “Generación D” initiative, Red.es, Ministerio para la Transformación Digital y de la Función Pública, for talent attraction (C005/24-ED CV1), funded by the European Union NextGenerationEU funds through PRTR. The authors also acknowledge the crowdfunding initiative #Yomecorono, available online at https://www.yomecorono.com., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model

  • Pons-Grífols, Anna
  • Tarrés Freixas, Ferran
  • Pérez Maíllo, Mónica
  • Riveira-Muñoz, Eva
  • Raïch-Regué, Dàlia
  • Perez-Zsolt, Daniel
  • Muñoz Basagoiti, Jordana
  • Tondelli, Barbara
  • Pradenas, Edwards
  • Izquierdo-Useros, Nuria
  • Capdevila, Sara
  • Vergara-Alert, Júlia
  • Urrea, Victor
  • Carrillo, Jorge
  • Ballana, Ester
  • Forrow, Stephen
  • Clotet, Bonaventura
  • Segalés, Joaquim
  • Trinité, Benjamin
  • Blanco, Julià
Animal models have been instrumental in elucidating the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and in testing coronavirus disease 2019 (COVID-19) vaccines and therapeutics. Wild-type (WT) mice are not susceptible to many SARS-CoV-2 variants, and therefore, transgenic K18-hACE2 mice have emerged as a standard model system. However, this model is characterized by a severe disease, particularly associated with neuroinfection, which leads to early humane endpoint euthanasia. Here, we established a novel knock-in (KI) mouse model by inserting the original K18-hACE2 transgene into the collagen type I alpha chain (COL1A1) locus using a recombinase-mediated cassette exchange (RMCE) system. Once the Col1a1-K18-hACE2 mouse colony was established, animals were challenged with a B.1 SARS-CoV-2 (D614G) isolate and were monitored for up to 14 days. Col1a1-K18-hACE2 mice exhibited an initial weight loss similar to the K18-hACE2 transgenic model but did not develop evident neurologic clinical signs. The majority of Col1a1-K18-hACE2 mice did not reach the pre-established humane endpoint, showing a progressive weight gain 9 days postinfection (dpi). Importantly, despite this apparent milder pathogenicity of the virus in this mouse model compared to the K18-hACE2 transgenic model, high levels of viral RNA were detected in the lungs, oropharyngeal swab, and nasal turbinates. Moreover, the remaining lesions and inflammation in the lungs were still observed 14 dpi. In contrast, although low-level viral RNA could be detected in a minority of Col1a1-K18-hACE2 animals, no brain lesions were observed at any timepoint. Overall, Col1a1-K18-hACE2 mice constitute a new model for investigating SARS-CoV-2 pathogenesis and treatments, with potential implications for studying long-term COVID-19 sequelae., The authors would like to acknowledge Jorge Díaz, Yaiza Rosales-Salgado, Rosa María Ampudia-Carrasco, Sergi Sunyé-Casas, and Mireia Martínez from the CMCiB for their essential help in the BSL3 facility and the K18-hACE2 mouse colony. We also thank Marisa Larramona from Parc Científic de Barcelona for her invaluable help with the knock-in mouse colony. We thank the Dormeur Fondation for their financial support for the acquisition of the QuantStudio-5 real-time PCR system. A.P.-G. was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2022 FI_B 00698). This study was funded by Grifols, the Departament de Salut of the Generalitat de Catalunya (grant nos. SLD016 to J.B. and SLD015 to J.C.), the Spanish Health Institute Carlos III, CERCA Programme/Generalitat de Catalunya 2021 SGR 00452, and the crowdfunding initiatives #joemcorono, BonPreu/Esclat, and Correos. N.I.-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00, PID2020-117145RB-I00, and 10.13039/501100011033, Spain), the EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and the institutional funding of Pharma Mar, Grifols, HIPRA, and Amassence. The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication. A.P.-G., F.T.-F., B. Trinité, and J.B. conceived and designed the experiments. A.P.-G., F.T.-F., and B. Trinité performed the animal procedures. A.P.-G., F.T.-F., M.P., E.R.-M., D.R.-R., D.P.-Z., J.M.-B., E.P., J.S., and B. Trinité performed the analytical experiments. A.P.-G., B. Trinité, J.S., J.V.-A., V.U., and J.B. analyzed and interpreted the data. S.F. and B. Tondelli established and provided the knock-in mouse colony. S.C. established communication between animal facilities and contributed to the veterinary report verification to allow the knock-in animal shipment to the CMCiB facility. D.P.-Z., J.M.-B., D.R.-R., and N.I.-U. provided key reagents. A.P.-G., B. Trinité, and J.B. wrote the paper. All authors contributed to the article and approved the submitted version., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Highly Efficient Air Sterilization via Low-Temperature Interfacial Evaporation in Inductively Heated Superhydrophilic Ferromagnetic Filters

  • Fons, Arnau
  • Vaca, Cristina
  • Franco-Trepat, Eloi
  • Lafuente, Aritz
  • Tajada Herráiz, José Luis
  • Serrà, Albert
  • Díaz Pedroza, Jorge
  • Franco, Sandra
  • Boreika, Rytis
  • Erkizia, Itziar
  • Izquierdo-Useros, Núria
  • López-Ortega, Alberto
  • Garaio, Eneko
  • Esplandiú, María J.
  • Nogués, Josep
  • Sepúlveda, Borja
The scientific evidence supporting airborne transmission of pathogens in closed spaces highlights the inefficiency of current air circulation and filtration technologies (e.g., HEPA filters, UV, ozone, ionization) in preventing the spread of airborne pathogens. This underscores the urgent need for new air disinfection devices. Here, the first air sterilization technology is presented based on low-temperature interfacial evaporation. This novel approach integrates superhydrophilic micro/nano-structured stainless-steel filters and ultra-efficient magnetic inductive heating to enable complete evaporation of water from the contaminated aerosols and the precipitation of all the organic and inorganic residues within the filter at temperatures in the range of 60-80 °C. The technology is validated through experiments with contaminated aerosols with different active viruses, including SARS-CoV-2 and respiratory syncytial virus (RSV), demonstrating the elimination of 99.6% or more of the nebulized viruses, at filter temperatures of 60-80 °C and airflow rates of 15 L min-1. The filters also support pyrolytic self-cleaning and reuse, ensuring extended service time and minimal maintenance. This air sterilization technology represents a significant advancement over existing state-of-the-art filtering technology, offering unmatched versatility, low energy consumption, and cost-effective sterilization, without generating harmful radicals, dangerous high voltages, or high temperatures., A.F., C.V., and E.F.-T. contributed equally to this work. Ministerio de Ciencia e Innovación (MICIN) is acknowledged through Grant PDC2021-121303-I00, funded by NextGenerationEU and MICIU/AEI/10.13039/501100011033. MICIN is also acknowledged through Grants PID2021-124568NB-I00, PDI2022-138588OB-C31 and PDI2022-138588OB-C32 funded by MICIU/AEI/10.13039/501100011033. The IMB is supported by the Maria de Maeztu Centres of Excellence program Grant CEX2023-001397-M and the ICN2 is supported by the Severo Ochoa Centres of Excellence program, Grant CEX2021-001214-S, both funded by MCIU/AEI/10.13039/501100011033. ICN2 is funded by the CERCA program/Generalitat de Catalunya. The authors acknowledge the funding from 2021-SGR-00651 project by the Generalitat de Catalunya. N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 and 10.13039/ 501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and by institutional funding of PharmaMar, Grifols, HIPRA, and Amassence. The authors also thank the support of 2021 SGR 00452, CERCA and Fundación Dormeur. E.F.-T. is supported by JDC2023-050389-I and A.L.O. by CNS2022-135787 funded by MCIU/AEI/10.13039/ 501100011033, European Union NextGenerationEUPRTR and FSE+, With funding from the Spanish government through the "María de Maeztu Unit of Excellence" accreditation (CEX2023-001397-M), With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001214-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor

  • Jimeno, Jose
  • Varona, Jose Felipe
  • Lopez-Martin, Jose A
  • Izquierdo-Useros, Nuria
  • Molina Molina, Elisa
  • Guisado-Vasco, Pablo
  • Sachse, Martin
  • Risco, Cristina
  • Losada, Alejandro
  • Fudio, Salvador
  • Luepke, Erik
  • Nieto, Antonio
  • Gomez, Javier
  • Aviles, Pablo
  • Cuevas, Carmen
  • Bouhaddou, Mehdi
  • Solá Gurpegui, Isabel
  • Krogan, Nevan J
  • Enjuanes Sánchez, Luis
  • Fernandez-Sousa, Jose M
  • GarcÍa-Sastre, Adolfo
  • White, Kris
Selective pressures in the ocean promote the evolution of potent molecules that may be useful in therapeutic settings. Tunicates provide a rich source of bioactive molecules that have been shown to have anti-neoplastic and anti-microbial activities. Plitidepsin, a natural marine cyclic depsipeptide originally isolated from the tunicate Aplidium albicans, was originally developed as an anti-tumor drug, and has been approved for use in Australia in patients with advanced pretreated myeloma. Early in the SARS-CoV-2 pandemic, plitidepsin was shown to have potent preclinical efficacy against the virus, suggesting that it could be repurposed for the treatment of COVID-19. This review summarizes the clinical development of plitidepsin first as an anti-tumor drug, before providing a recapitulation of current efforts to repurpose the molecule as an antiviral therapy. The pharmacokinetic and pharmacodynamic data on plitidepsin will be analyzed, and the various experimental lines of evidence in support of the molecule's multifactorial mechanism of action will be explored. Finally, the available data on the use of plitidepsin in patients with COVID-19 will be presented, including results from a Phase I proof-of-concept study, real-world data from immunocompromised patients, and a look of results from a Phase III clinical trial that confirms the working hypothesis., The studies described in this manuscript were primarily funded by PharmaMar, which supported the preclinical development, mechanistic studies, and clinical trials of plitidepsin in cancer and SARS-CoV-2 infection. This includes work contributed by AL, PA, CC, SF, EL, AN, JG, CR, MS, IS, LE, JFV, PGV, JALM, and JJ. NI-U was supported by the Spanish Ministry of Science and Innovation (grants PID2020-117145RB-I00, PID2023-147498OB-I00, and 10.13039/501100011033), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118), HORIZON-HLTH-2023-DISEASE-03, 2021 SGR 00452 (Generalitat de Catalunya/CERCA programme), and institutional funding from PharmaMar, Grifols, HIPRA, and Amassence. EM-M was supported by the Spanish Ministry of Science and Innovation (grant PRE2021-099271). Medical writing support by Timothy Silverstein, PhD (Feather Medical Communications), was funded by PharmaMar. A.G.-S. and N.J.K. acknowledge research support from the National Institutes of Health (NIH) through R01AI137200 and R01AI153356. A.G.-S. also acknowledges support from R01AI163011, R35GM137905, R01HL169500, and the Mount Sinai Dean's Fund for COVID-19 Research. N.J.K. also acknowledges institutional support from the Gladstone Institutes and the Roddenberry Foundation., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes

  • Molina Molina, Elisa
  • Bech-Serra, Joan Josep
  • Franco-Trepat, Eloi
  • Jarne, Ignasi
  • Perez-Zsolt, Daniel
  • Badia, Roger
  • Riveira-Muñoz, Eva
  • Garcia-Vidal, Edurne
  • Revilla, Lluís
  • Franco, Sandra
  • Tarrés Freixas, Ferran
  • Roca, Núria
  • Ceada, Gerardo
  • Kochanowski, Karl
  • Raïch-Regué, Dàlia
  • Erkizia, Itziar
  • Boreika, Rytis
  • Bordoy, Antoni E.
  • Soler, Laia
  • Guil, Sonia
  • Carrillo, Jorge
  • Blanco, Julià
  • Martínez, Miguel Ángel
  • Paredes, Roger
  • Losada, Alejandro
  • Aviles, Pablo
  • Cuevas, Carmen
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Ballana, Ester
  • de la Torre, Carolina
  • Izquierdo-Useros, Nuria
Plitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preserving cellular viability. In response to plitidepsin, cells upregulate EIF2AK3 and proteins that reduce translation, but also proteins that support proteostasis via ribosome synthesis and cap-independent translation by eIF4G2 and IGF2BP2. While plitidepsin inhibits cap- or internal ribosome entry sites (IRES)-mediated translation, its impact on N6-methyladenosine (m6A) translation is limited. In agreement, plitidepsin blocks members of Coronaviridae, Flaviviridae, Pneumoviridae and Herpesviridae families. Yet, it fails to inhibit retroviruses that exploit m6A synthesis routes and are blocked by drugs targeting IGF2BP2 m6A reader. By deciphering the molecular fingerprint of cells treated with therapies targeting translation we identify a rational approach to select broad-spectrum antivirals with potential to counteract future pandemic viruses., N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2020-117145RB-I00, PID2023-147498OB-I00 and 10.13039/501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union) and by institutional funding of PharmaMar, Grifols, HIPRA, and Amassence. E.M-M. is supported by the Spanish Ministry of Science and Innovation (grant PRE2021-099271). E.F-T is supported by JDC2023-050389-I funded by MCIU/AEI/10.13039/501100011033 and FSE+. E.G-V. is a research fellow from PERIS (SLT017/20/000090). E.B. and R.B. are research fellows from ISCIII-FIS (CPII19/00012; CP19/00011). K.K. is supported by funding from the Spanish Ministry of Research and Innovation (RYC2021-033035-I/AEI/10.13039/501100011033). G.C. is supported with funding from PLEC2022-009171/AEI/10.13039/501100011033. IrsiCaixa is supported by 2021 SGR 0045. The proteomic analyses were conducted at the IJC Proteomics Unit, which is affiliated with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Spanish Platform of Molecular and Bioinformatics Resources (ProteoRed), Instituto de Salud Carlos III (PT17/0019), and CERCA GINYNS. This unit serves as a gateway to scientific and technical infrastructures. We acknowledge J. Díaz from the CMCiB for his constant help at the BSL3 facility. We thank the contribution of E. Martró and V. Saludes from the Microbiology department of HUGTIP for their constant help to identify and sequence SARS-CoV-2 variants. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com) and Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real-time PCR system and an Eclipse Ts2RFL inverted research microscope., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model

  • Pons-Grífols, Anna
  • Tarrés Freixas, Ferran
  • Pérez Maíllo, Mónica
  • Riveira-Muñoz, Eva
  • Raïch-Regué, Dàlia
  • Perez-Zsolt, Daniel
  • Muñoz Basagoiti, Jordana
  • Tondelli, Barbara
  • Pradenas, Edwards
  • Izquierdo-Useros, Nuria
  • Capdevila, Sara
  • Vergara-Alert, Júlia
  • Urrea, Victor
  • Carrillo, Jorge
  • Ballana, Ester
  • Forrow, Stephen
  • Clotet, Bonaventura
  • Segalés, Joaquim
  • Trinité, Benjamin
  • Blanco, Julià
Animal models have been instrumental in elucidating the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and in testing coronavirus disease 2019 (COVID-19) vaccines and therapeutics. Wild-type (WT) mice are not susceptible to many SARS-CoV-2 variants, and therefore, transgenic K18-hACE2 mice have emerged as a standard model system. However, this model is characterized by a severe disease, particularly associated with neuroinfection, which leads to early humane endpoint euthanasia. Here, we established a novel knock-in (KI) mouse model by inserting the original K18-hACE2 transgene into the collagen type I alpha chain (COL1A1) locus using a recombinase-mediated cassette exchange (RMCE) system. Once the Col1a1-K18-hACE2 mouse colony was established, animals were challenged with a B.1 SARS-CoV-2 (D614G) isolate and were monitored for up to 14 days. Col1a1-K18-hACE2 mice exhibited an initial weight loss similar to the K18-hACE2 transgenic model but did not develop evident neurologic clinical signs. The majority of Col1a1-K18-hACE2 mice did not reach the pre-established humane endpoint, showing a progressive weight gain 9 days postinfection (dpi). Importantly, despite this apparent milder pathogenicity of the virus in this mouse model compared to the K18-hACE2 transgenic model, high levels of viral RNA were detected in the lungs, oropharyngeal swab, and nasal turbinates. Moreover, the remaining lesions and inflammation in the lungs were still observed 14 dpi. In contrast, although low-level viral RNA could be detected in a minority of Col1a1-K18-hACE2 animals, no brain lesions were observed at any timepoint. Overall, Col1a1-K18-hACE2 mice constitute a new model for investigating SARS-CoV-2 pathogenesis and treatments, with potential implications for studying long-term COVID-19 sequelae., The authors would like to acknowledge Jorge Díaz, Yaiza Rosales-Salgado, Rosa María Ampudia-Carrasco, Sergi Sunyé-Casas, and Mireia Martínez from the CMCiB for their essential help in the BSL3 facility and the K18-hACE2 mouse colony. We also thank Marisa Larramona from Parc Científic de Barcelona for her invaluable help with the knock-in mouse colony. We thank the Dormeur Fondation for their financial support for the acquisition of the QuantStudio-5 real-time PCR system. A.P.-G. was supported by a predoctoral grant from Generalitat de Catalunya and Fons Social Europeu (2022 FI_B 00698). This study was funded by Grifols, the Departament de Salut of the Generalitat de Catalunya (grant nos. SLD016 to J.B. and SLD015 to J.C.), the Spanish Health Institute Carlos III, CERCA Programme/Generalitat de Catalunya 2021 SGR 00452, and the crowdfunding initiatives #joemcorono, BonPreu/Esclat, and Correos. N.I.-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00, PID2020-117145RB-I00, and 10.13039/501100011033, Spain), the EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and the institutional funding of Pharma Mar, Grifols, HIPRA, and Amassence. The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication. A.P.-G., F.T.-F., B. Trinité, and J.B. conceived and designed the experiments. A.P.-G., F.T.-F., and B. Trinité performed the animal procedures. A.P.-G., F.T.-F., M.P., E.R.-M., D.R.-R., D.P.-Z., J.M.-B., E.P., J.S., and B. Trinité performed the analytical experiments. A.P.-G., B. Trinité, J.S., J.V.-A., V.U., and J.B. analyzed and interpreted the data. S.F. and B. Tondelli established and provided the knock-in mouse colony. S.C. established communication between animal facilities and contributed to the veterinary report verification to allow the knock-in animal shipment to the CMCiB facility. D.P.-Z., J.M.-B., D.R.-R., and N.I.-U. provided key reagents. A.P.-G., B. Trinité, and J.B. wrote the paper. All authors contributed to the article and approved the submitted version., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Airway organoids reveal patterns of influenza A tropism and adaptation in wildlife species

  • Tarrés Freixas, Ferran
  • Ceada, Gerardo
  • Català-Moll, Francesc
  • Casadellà, Maria
  • Tolosa-Alarcón, Sara
  • Franco-Trepat, Eloi
  • Boreika, Rytis
  • Almagro-Delgado, Vanessa
  • Carmona, Noelia
  • Estruch, Josep
  • Fernández-Bellon, Hugo
  • Fuentes-Moyano, Laura
  • Molina-López, Rafael
  • Navarro, Nuria
  • Parera, Mariona
  • Pérez Simó, Marta
  • Repullés, Joan
  • Roca, Núria
  • Torne, Odalys
  • Velarde, Roser
  • Valencia, Alfonso
  • Paredes, Roger
  • Izquierdo-Useros, Nuria
  • Romero-Durana, Miguel
  • Kochanowski, Karl
  • Vergara-Alert, Júlia
Identifying animal species that are susceptible to the plethora of existing and emerging viruses is critical for predicting and containing disease outbreaks. Current efforts to assess viral tropism largely rely on experimental infection models, but such experiments are logistically and ethically infeasible for many wildlife species. To tackle this challenge, we developed a panel of airway organoids from ten taxonomically diverse wildlife and livestock species and evaluated their susceptibility to influenza viruses of mammalian (pH1N1) and avian (H5N1) origin. Our analyses revealed large host-specific differences in infection rate and cytopathogenicity that aligned with known in vivo data and field observations. Furthermore, we demonstrated that this organoid panel can serve as a powerful tool to elucidate receptor-binding mechanisms, viral dynamics and early host adaptation in poorly characterized animal hosts. In summary, this work provides a robust and ethically viable approach for evaluating viral tropism and adaptation in wildlife species, and may aid current pandemic preparedness, zoonotic disease surveillance and wildlife conservation efforts., This project was supported by a “Proyectos en lineas estratégicas” grant from the Spanish Ministry of Research and Innovation (project ID: PLEC2022-009171 /AEI/10.13039/501100011033). KK acknowledges additional support by the Spanish Ministry of Research and Innovation (RYC2021-033035-I /AEI/10.13039/501100011033). N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 /AEI/10.13039/501100011033), EU HORIZON-HLTH-2021 CORONA-01 (grant 101046118), EU HORIZON-HLTH-2023-DISEASE-03, and by institutional funding from PharmaMar, HIPRA, Amassence and Smart Vitamins. NIU is part of PTI-CSIC Salud Global. The authors also thank the support of CERCA and Fundación Dormeur. E.F.-T. is supported by JDC2023050389-I. MRD was supported by a fellowship within the “Generación D” initiative, Red.es, Ministerio para la Transformación Digital y de la Función Pública, for talent attraction (C005/24-ED CV1), funded by the European Union NextGenerationEU funds through PRTR. The authors also acknowledge the crowdfunding initiative #Yomecorono, available online at https://www.yomecorono.com., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Optimized ACE2-Fc fusion proteins with picomolar neutralization activity against highly evolved SARS-CoV-2 variants

  • Abancó, Ferran
  • Tarrés Freixas, Ferran
  • Lepore, Rosalba
  • Molina-Molina, Elisa
  • Franco, Eloi
  • Boreika, Rytis
  • Pradenas, Edwards
  • Raïch-Regué, Dàlia
  • Erkizia, Itziar
  • Clotet, Bonaventura
  • Valencia, Alfonso
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Trinité, Benjamin
The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compromised the efficacy of many authorized monoclonal antibody products. This highlights the need for alternative strategies, especially for vulnerable populations such as immunocompromised individuals. Here, we optimized angiotensin-converting enzyme 2 (ACE2)-Fc fusion proteins by combining three engineering steps: in silico mutagenesis of the S protein binding interface to increase affinity, insertion of a flexible linker to improve protein stability and S protein accessibility, and generation of a tetrameric molecule to maximize avidity. Neutralizing activity was tested against a large panel of pre-Omicron and Omicron pseudoviruses and authentic viruses, including JN.1 and KP.2 variants. Optimized ACE2-Fc molecules demonstrated potent neutralizing activity, in the picomolar range, against all SARS-CoV-2 variants. Our molecules displayed similar potency but better resilience when compared to the monoclonal antibody Sipavibart. These findings support ACE2-Fc proteins as robust candidates for next-generation interventions against infection by an evolving SARS-CoV-2., We acknowledge Carmen Aguilar-Gurrieri from IrsiCaixa for her help on initial structural analysis and Jorge Díaz from CMCiB for his help at the BSL3 facility. We also acknowledge Carlo Carolis and Katrina Broadbent from CRG for their work on surface plasmon resonance. Benjamin Trinité was funded by Project DTS23009 from the Spanish “Instituto de Salud Carlos III (ISCIII)-Subdirección General de Evaluación” and “Fondo Europeo de Desarrollo Regional (FEDER).” Julià Blanco was partially funded by the crowdfunding initiative #joemcorono, GRIFOLS, and the Fundació Glòria Soler. Nuria Izquierdo-Useros is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 and 10.13039/501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and by institutional funding from PharmaMar, GRIFOLS, HIPRA, and Amassence. Eloi Franco is supported by JDC2023-050389-I funded by MCIU/AEI/10.13039/501100011033 and FSE+. IrsiCaixa and IRTA are funded by the CERCA program/Generalitat de Catalunya. We acknowledge the funding from 2021-SGR-00651 project, 2021-SGR-01385, and 2021-SGR-00825 projects by the Generalitat de Catalunya., info:eu-repo/semantics/publishedVersion